Mankind Pharma: Business Overview & Financial Analysis
Mankind Pharma Limited is a domestic-focused Indian pharmaceutical company headquartered in New Delhi. The company develops, manufactures, and markets branded generic formulations, consumer healthcare products, active pharmaceutical ingredients (APIs), and super-specialty biopharmaceuticals. Its core prescription portfolio covers cardiovascular, anti-diabetic, anti-infectives, gastrointestinal, respiratory, and gynaecology therapies, alongside leading consumer brands such as Manforce, Prega News, and Gas-o-Fast. Mankind Pharma operates more than 30 manufacturing facilities across India and an extensive distribution network that reaches over 80% of medical prescribers nationwide.
Segment Revenue & Business Mix of Mankind Pharma (FY26)
The domestic business continues to be the company's largest revenue contributor, supported by growing exports and a strong consumer healthcare portfolio.
- Domestic Prescription Business (Rx ex-CH) – Rs 11,338 crore (79.4%)
- Exports Business – Rs 2,061 crore (14.4%)
- Consumer Healthcare Business (CH) – Rs 879 crore (6.2%)
- Total Revenue from Operations – Rs 14,278 crore (100.0%)
Domestic operations remain the primary profit engine for Mankind Pharma, contributing nearly 85.6% of consolidated revenue when consumer healthcare is included. The export business grew 34.5% year-on-year in FY26, supported by international expansion and the integration of Bharat Serums and Vaccines (BSV) global assets. The domestic prescription business also grew 14.9% year-on-year, driven by strong volume growth in chronic therapies and new product launches.
Domestic Prescription Portfolio & Therapy Share of Mankind Pharma (Q4 FY26 & FY26)
The company continues to strengthen its leadership in the Indian prescription market through its wide doctor reach and growing chronic therapy portfolio.
- Domestic Prescriber Penetration – 84.2% of Indian doctors
- Chronic Therapy Contribution – 40.0% of domestic Rx sales
- Brand Families >Rs 200 Crore – 13 brand families
- Secondary Sales Ranking – 4th largest in Indian Pharmaceutical Market (IPM)
- Domestic Rx Revenue (Q4 FY26) – Rs 2,886 crore (+13.4% YoY)
Mankind Pharma maintains a domestic prescription market share of approximately 15.2% across India. Chronic therapies contributed 40% of domestic prescription sales, supported by 14.7% growth in cardiovascular products and 11.6% growth in anti-diabetic products during Q4 FY26. Key brands including Telmikind, Lipirose, and Glyzid continued to outperform the market.
Consumer Healthcare & OTC Division of Mankind Pharma (Q4 FY26 & FY26)
The consumer healthcare business continues to benefit from strong brand leadership and expanding digital distribution.
- Prega News (Pregnancy Test Kits) – No. 1 brand (80%+ category share)
- Manforce (Condoms & Sexual Wellness) – No. 1 brand (30%+ category share)
- Gas-o-Fast (Antacid Powder) – Top 3 brand in category
- Modern Trade & E-Commerce Contribution – 13% of OTC sales
- Consumer Healthcare Revenue (Q4 FY26) – Rs 203 crore (+20.0% YoY)
The Consumer Healthcare division generated Rs 879 crore in FY26, supported by leading OTC brands and rapid growth across e-commerce channels. Modern trade and e-commerce sales increased 57% year-on-year during FY26, while secondary sales of Gas-o-Fast and Prega News grew 24% and 28% year-on-year, respectively, during Q4 FY26.
Manufacturing Infrastructure & R&D Capabilities of Mankind Pharma (FY26)
The company has a strong manufacturing and research base that supports both domestic and international operations.
- Total Manufacturing Units – 30+ facilities across India
- In-House R&D Centres – 4 research locations
- R&D Expenditure – 2.5% to 3.0% of annual revenues
- Total Employee Workforce – 22,000+ professionals
- Dedicated Field Force Strength – 16,000+ sales representatives
Mankind Pharma operates integrated formulation and API manufacturing facilities across Himachal Pradesh, Uttarakhand, Sikkim, and Andhra Pradesh. Its Udaipur manufacturing facility received EU-GMP certification during FY26, strengthening export capabilities. The company's R&D teams continue to focus on complex generics, novel drug delivery systems (NDDS), and complex biopharmaceutical formulations.
BSV Acquisition & Super-Specialty Business of Mankind Pharma (FY26)
The acquisition of Bharat Serums and Vaccines has significantly strengthened the company's presence in specialty pharmaceuticals.
- Acquisition Transaction Value – Rs 13,630 crore enterprise value
- BSV Product Portfolio Focus – Women's Health, Assisted Reproductive Technology (ART), Critical Care, Immunoglobulins
- Acute Segment Exposure in BSV – 83% of domestic portfolio
- Net Debt Impact – Net Debt to Adjusted EBITDA at 1.3x post-acquisition
- Integration Synergy Runway – 15% to 18% projected cost and distribution synergies
The acquisition of Bharat Serums and Vaccines (BSV) transformed Mankind Pharma into a market leader in specialty biopharmaceuticals and complex injectables. BSV operates in specialised therapeutic segments with high entry barriers and limited generic competition. The company is also realising synergies by combining Mankind's strong doctor network with BSV's hospital and gynaecology portfolio.
Financial Performance & Margin Profile of Mankind Pharma (Q4 FY26 & FY26)
The company reported healthy revenue growth, improving margins, and strong cash flow generation during FY26.
- Q4 FY26 Consolidated Revenue – Rs 3,443 crore (+11.8% YoY)
- Q4 FY26 Adjusted EBITDA Margin – 27.1% (+400 bps YoY)
- Q4 FY26 Consolidated PAT – Rs 559 crore (+31.7% YoY)
- FY26 Full Year Revenue – Rs 14,278 crore (+17.0% YoY)
- FY26 Full Year Adjusted EBITDA – Rs 3,629 crore (+14.9% YoY)
- FY26 Operating Cash Flow to EBITDA Ratio – 89%
Consolidated revenue reached Rs 14,278 crore in FY26, supported by double-digit domestic growth and the consolidation of BSV. Adjusted EBITDA margin improved to 27.1% during Q4 FY26 due to stable raw material costs, operating leverage, and a higher contribution from chronic therapies. Operating cash flow conversion also strengthened, with the CFO-to-EBITDA ratio improving to 89% in FY26 from 80% in FY25.
Balance Sheet & Capital Allocation Metrics of Mankind Pharma (FY26)
The company continues to maintain a strong balance sheet while reducing debt following the BSV acquisition.
- Cash & Liquid Equivalents – Rs 2,398 crore
- Net Debt to Adjusted EBITDA Ratio – 1.3x
- Return on Capital Employed (ROCE) – ~16.6% (ex-BSV acquisition)
- Total Capital Expenditure (9M FY26) – Rs 470 crore
- Commercial Paper Repayment – Rs 1,500 crore debt paid down in Q3 FY26
Mankind Pharma continues to strengthen its balance sheet through steady deleveraging after the BSV acquisition. Commercial paper worth Rs 1,500 crore was fully repaid during FY26, reducing interest costs. Capital expenditure remains focused on brownfield expansion projects and is expected to stay within 3.8% to 4.3% of annual revenue.
Management Commentary & Strategic Outlook of Mankind Pharma (FY26–FY27)
Management remains focused on strengthening chronic therapies, integrating BSV, expanding exports, and reducing debt.
- Management targets sustaining a 1.2x to 1.4x outperformance over the broader Indian Pharmaceutical Market (IPM) in core chronic therapies.
- Chronic share of domestic prescription sales is guided to expand further toward 42% to 45% over the medium term.
- Remedial actions in acute therapies like Gastrointestinal and Vitamins have stabilized trade inventory and restored sequential volume growth.
- Integration of BSV is progressing as planned, with double-digit domestic growth and margin expansion expected across super-specialty verticals.
- Consumer Healthcare division restructuring will focus on expanding direct retail distribution while growing modern trade and e-commerce contribution to >15%.
- R&D spends will be maintained in the range of 2.5% to 3.0% of annual revenues, prioritizing complex generics and complex injectables.
- Net debt reduction remains a priority, with internal cash flows targeted toward deleveraging to bring Net Debt to EBITDA below 1.0x over 18 to 24 months.
- Export growth will be driven by expanding BSV's specialty portfolio across emerging markets and selective ANDA launches in regulated geographies.
The company plans to continue outperforming the Indian pharmaceutical market by expanding its chronic therapy portfolio, strengthening consumer healthcare, integrating BSV, increasing exports, and reducing debt through strong internal cash generation.
Sources & References
- Mankind Pharma Limited Q4 & FY26 Consolidated Financial Results & Press Release (May 2026)
- Mankind Pharma Limited Q3 FY26 Investor Presentation & Earnings Summary (Feb 2026)
- Mankind Pharma Limited Q3 FY26 Earnings Conference Call Transcript (Feb 2026)
- BSE India & NSE Official Corporate Announcements & Filings
- Ticker Finology Mankind Pharma Page
Want to filter out stocks using your own financial benchmarks? You can use the Stock Screener on Finology Ticker to identify and compare companies based on specific growth and efficiency metrics.
Disclaimer
The information presented above on Mankind Pharma Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Mankind Pharma Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.